Rutgeerts RUTGEERTSShow email address
Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium. | University Hospital Gasthuisberg, Leuven, Belgium | University ...
Is this your profile? Claim your profile Copy URL Embed Link to your profile
Rutgeerts RUTGEERTS:Expert Impact
Concepts for whichRutgeerts RUTGEERTShas direct influence:Ulcerative colitis,Crohns disease,Inflammatory bowel disease,Crohn disease,Mucosal healing,Inflammatory bowel,Bowel disease,Certolizumab pegol.
Rutgeerts RUTGEERTS:KOL impact
Concepts related to the work of other authors for whichfor which Rutgeerts RUTGEERTS has influence:Inflammatory bowel disease,Ulcerative colitis,Gut microbiota,Mucosal healing,Ibd patients,Necrosis factor,Clinical remission.
KOL Resume for Rutgeerts RUTGEERTS
Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
University Hospital Gasthuisberg, Leuven, Belgium
Division of Gastroenterology and Hepatology, University of Leuven, Gasthuisberg, Leuven, Belgium.
Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium
Department of Hepatogastroenterology and Digestive Oncology, Haut-Lévêque Hospital, CHU de Bordeaux, Bordeaux, France.
Department of Gastroenterology, University of Leuven, Leuven, Belgium
Department of Gastroenterology, Hospital Gasthuisberg, Leuven, Belgium
KU Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), University Hospitals Leuven, Leuven, Belgium.
Department of Gastroenterology University Hospital Gasthuisberg Leuven Belgium
Department of Gastroenterology, University Hospital Gasthuisberg, KU Leuven, Belgium
Veterans Affairs Center for Outcomes Research and Education, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
University of Leuven Hospitals, Belgium
Department of Gastro-Enterologie, University Hospital of Gasthuisberg, Leuven, Belgium
Orebro University Hospital, Orebro, N/A, Sweden,
|patients colon tissues||#1|
|positive response infliximab||#1|
|endoscopic activity scores||#1|
|trough ifx dis||#1|
|normals chenodeoxycholic acid||#1|
|growth factors inflammation||#1|
|sustained infliximab treatment||#1|
|continued dosing tcs||#1|
|pouchitis active uc||#1|
|induction cell type||#1|
|surrogate serum marker||#1|
|uc gene expression||#1|
|jc viral loads||#1|
|12 caucasian cohorts||#1|
|inulin lactobacillus shirota||#1|
|ifx restorative proctocolectomy||#1|
|protein assimilation humans||#1|
|intravenous ustekinumab week||#1|
|infliximab therapy hrql||#1|
|tolerability infusion reactions||#1|
|response crp levels||#1|
|regions belgian population||#1|
|solids basal condition||#1|
|tcrcd3 complex ni0401||#1|
|new pteridine derivative||#1|
|ibd pathogenetic mechanisms||#1|
|Sign-in to see all concepts, it's free!|
Prominent publications by Rutgeerts RUTGEERTS
BACKGROUND: Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor alpha, is an established treatment for Crohn's disease but not ulcerative colitis.
METHODS: Two randomized, double-blind, placebo-controlled studies--the Active Ulcerative Colitis Trials 1 and 2 (ACT 1 and ACT 2, respectively)--evaluated the efficacy of infliximab for induction and maintenance therapy in adults with ulcerative colitis. In each study, 364 patients with moderate-to-severe active ...
|Known for Ulcerative Colitis | Placebo Infliximab | Week Patients | Antinuclear Antibodies | Maintenance Therapy|
BACKGROUND: The efficacy of vedolizumab, an α4β7 integrin antibody, in Crohn's disease is unknown.
METHODS: In an integrated study with separate induction and maintenance trials, we assessed intravenous vedolizumab therapy (300 mg) in adults with active Crohn's disease. In the induction trial, 368 patients were randomly assigned to receive vedolizumab or placebo at weeks 0 and 2 (cohort 1), and 747 patients received open-label vedolizumab at weeks 0 and 2 (cohort 2); disease status was ...
|Known for Vedolizumab Placebo | Maintenance Therapy | Week Patients | Cdai100 Response | Active Crohns Disease|
[ PUBLICATION ]
BACKGROUND: Adalimumab induced clinical remission after four weeks in patients with active Crohn's disease in the CLASSIC I trial.
OBJECTIVE: To evaluate long term efficacy and safety of adalimumab maintenance therapy in Crohn's disease in a follow-on randomised controlled trial (CLASSIC II).
METHODS: In the preceding CLASSIC I trial, 299 patients with moderate to severe Crohn's disease naive to tumour necrosis factor antagonists received induction therapy with adalimumab 40 mg/20 mg, 80 ...
|Known for Maintenance Treatment | Weeks Patients | Remission Week | Antinuclear Antibodies | Adalimumab 40|
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial
[ PUBLICATION ]
BACKGROUND: Biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein, have been recommended for monitoring patients with Crohn's disease, but whether their use in treatment decisions improves outcomes is unknown. We aimed to compare endoscopic and clinical outcomes in patients with moderate to severe Crohn's disease who were managed with a tight control algorithm, using clinical symptoms and biomarkers, versus patients managed with a clinical management ...
|Known for Tight Control | Disease Clinical | Patients Crohn | 3 Trial | Primary Endpoint|
Histamine Receptor H1–Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome
[ PUBLICATION ]
BACKGROUND & AIMS: Histamine sensitizes the nociceptor transient reporter potential channel V1 (TRPV1) and has been shown to contribute to visceral hypersensitivity in animals. We investigated the role of TRPV1 in irritable bowel syndrome (IBS) and evaluated if an antagonist of histamine receptor H1 (HRH1) could reduce symptoms of patients in a randomized placebo-controlled trial.
METHODS: By using live calcium imaging, we compared activation of submucosal neurons by the TRPV1 agonist ...
|Known for Patients Ibs | Histamine Receptor | Abdominal Pain | Irritable Bowel Syndrome | Submucosal Neurons|
BACKGROUND: Gut-selective blockade of lymphocyte trafficking by vedolizumab may constitute effective treatment for ulcerative colitis.
METHODS: We conducted two integrated randomized, double-blind, placebo-controlled trials of vedolizumab in patients with active disease. In the trial of induction therapy, 374 patients (cohort 1) received vedolizumab (at a dose of 300 mg) or placebo intravenously at weeks 0 and 2, and 521 patients (cohort 2) received open-label vedolizumab at weeks 0 and ...
|Known for Maintenance Therapy | Ulcerative Colitis | Vedolizumab Placebo | Active Disease | Mayo Clinic|
Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial
[ PUBLICATION ]
BACKGROUND & AIMS: We investigated the efficacy of adalimumab for inducing and maintaining mucosal healing in patients with Crohn's disease (CD).
METHODS: A randomized, double-blind, placebo-controlled trial (extend the safety and efficacy of adalimumab through endoscopic healing [EXTEND]) evaluated adalimumab for induction and maintenance of mucosal healing in 135 adults with moderate to severe ileocolonic CD. The baseline degree of mucosal ulceration was documented by ileocolonoscopy. ...
|Known for Mucosal Healing | Adalimumab Patients | Extend Trial | Placebo Week | Induction Therapy|
BACKGROUND: We did a randomised controlled trial to assess the benefit of maintenance infliximab therapy in patients with active Crohn's disease who respond to a single infusion of infliximab.
METHODS: 573 patients with a score of at least 220 on the Crohn's disease activity index (CDAI) received a 5 mg/kg intravenous infusion of infliximab at week 0. After assessment of response at week 2, patients were randomly assigned repeat infusions of placebo at weeks 2 and 6 and then every 8 ...
|Known for Infliximab Week | Patients Groups | Randomised Trial | Variance Antibodies | Single Infusion|
Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis
[ PUBLICATION ]
BACKGROUND & AIMS: Subcutaneous golimumab, a fully human monoclonal antibody to tumor necrosis factor-α (TNFα), was evaluated as maintenance therapy in TNFα antagonist-naive adults with moderate-to-severe active ulcerative colitis, despite conventional therapy, who responded to golimumab induction therapy.
METHODS: We performed a phase 3, double-blind trial of patients who completed golimumab induction trials (Program of Ulcerative Colitis Research Studies Utilizing an Investigational ...
|Known for Patients Golimumab | Ulcerative Colitis | Induction Therapy | Clinical Response Week | Mucosal Healing|
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease
[ PUBLICATION ]
BACKGROUND: Episodic infliximab (IFX) treatment is associated with the formation of antibodies to IFX (ATIs) in the majority of patients, which can lead to infusion reactions and a shorter duration of response. Concomitant use of immunosuppressives (IS) reduces the risk of ATI formation.
AIMS AND METHODS: To investigate which of the IS-that is, methotrexate (MTX) or azathioprine (AZA)-is most effective at reducing the risk of ATI formation, a multicentre cohort of 174 patients with ...
|Known for Patients Atis | Immunosuppressive Therapy | Aza Mtx | Ifx Formation | Infliximab Infusions|
BACKGROUND & AIMS: Patients with moderate to severe ileocolonic Crohn's disease (CD) who received adalimumab induction and maintenance therapy had greater rates of mucosal healing than patients who received placebo after adalimumab induction therapy in a 52-week trial (EXTend the Safety and Efficacy of Adalimumab Through ENDoscopic Healing). We investigated whether this treatment also induced deep remission-a composite clinical and endoscopic end point.
METHODS: Rates of deep remission, ...
|Known for Deep Remission | Patients Adalimumab | Mucosal Ulceration | Week 52 | Crohn Disease|
Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
[ PUBLICATION ]
BACKGROUND & AIMS: There is an increasing need for new treatments for patients with Crohn's disease (CD) in whom previous therapy with tumor necrosis factor (TNF) antagonists has failed. We performed a placebo-controlled, phase 3, double-blind trial to evaluate the efficacy and safety of vedolizumab, an antibody against the integrin α4β7, as induction therapy.
METHODS: Patients with moderately to severely active CD (CD activity index [CDAI] score, 220-400 points) were assigned randomly ...
|Known for Vedolizumab Patients | Induction Therapy | Tumor Necrosis | Remission Week | Factor Antagonist|
BACKGROUND: Infliximab, a monoclonal antibody against tumor necrosis factor, is an effective maintenance therapy for patients with Crohn's disease without fistulas. It is not known whether infliximab is an effective maintenance therapy for patients with fistulas.
METHODS: We performed a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy of infliximab maintenance therapy in 306 adult patients with Crohn's disease and one or more draining abdominal or ...
|Known for Infliximab Maintenance Therapy | Patients Response | Crohns Disease Fistulas | Placebo Maintenance | Fistulizing Crohn|
BACKGROUND: The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for Crohn's disease are unknown.
METHODS: In this randomized, double-blind trial, we evaluated the efficacy of infliximab monotherapy, azathioprine monotherapy, and the two drugs combined in 508 adults with moderate-to-severe Crohn's disease who had not undergone previous immunosuppressive or biologic therapy. Patients were randomly assigned to receive an intravenous infusion of ...
|Known for Combination Therapy | Infliximab Azathioprine | Drugs Patients | Hormones Adult | Moderatetosevere Crohns Disease|